Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CURA-PRONE: Cisatracurium and Prone Positioning in ARDS
NCT06212492Recruiting
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cisatracurium in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Change in soluble form of the receptor for advanced glycation end products at Day 1. Started Aug 2024; status: recruiting.
02
Drugs
cisatracurium
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06212492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212492.